Key takeaways:

At 15 days, there were significant gains in mesopic low contrast distance visual acuity, as well as patient-reported night driving improvements.

The product will be prescription only.

In a phase 3 clinical trial, chronic night driving impairment in patients who underwent keratorefractive procedures improved after treatment with phentolamine ophthalmic solution 0.75%, according to a press release from Opus Genetics.

In the pivotal, double-masked LYNX-2 trial , 199 patients who reported decreased visual acuity under mesopic low contrast conditions following keratorefractive surgery were randomly assigned to receive either phentolamine or placebo and observed for 6 weeks. After 15 days of nightly administration in both eyes, 17.3% of treated patients had an improvement of

See Full Page